Last reviewed · How we verify
Administration of ceralasertib and olaparib
Administration of ceralasertib and olaparib is a Serine/threonine kinase inhibitor and PARP inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development for Breast cancer, Ovarian cancer.
PARP inhibitor
PARP inhibitor Used for Breast cancer, Ovarian cancer.
At a glance
| Generic name | Administration of ceralasertib and olaparib |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Serine/threonine kinase inhibitor and PARP inhibitor |
| Target | ATR and PARP1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Ceralasertib is a serine/threonine kinase inhibitor, while olaparib is a PARP inhibitor. The combination targets cancer cells with DNA repair deficiencies.
Approved indications
- Breast cancer
- Ovarian cancer
Common side effects
- Nausea
- Fatigue
- Vomiting
Key clinical trials
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (PHASE2)
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. (PHASE2)
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (PHASE2)
- AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
- Olaparib With Ceralasertib in Recurrent Osteosarcoma (PHASE2)
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (PHASE1, PHASE2)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of ceralasertib and olaparib CI brief — competitive landscape report
- Administration of ceralasertib and olaparib updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Administration of ceralasertib and olaparib
What is Administration of ceralasertib and olaparib?
Administration of ceralasertib and olaparib is a Serine/threonine kinase inhibitor and PARP inhibitor drug developed by AstraZeneca, indicated for Breast cancer, Ovarian cancer.
How does Administration of ceralasertib and olaparib work?
PARP inhibitor
What is Administration of ceralasertib and olaparib used for?
Administration of ceralasertib and olaparib is indicated for Breast cancer, Ovarian cancer.
Who makes Administration of ceralasertib and olaparib?
Administration of ceralasertib and olaparib is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
What drug class is Administration of ceralasertib and olaparib in?
Administration of ceralasertib and olaparib belongs to the Serine/threonine kinase inhibitor and PARP inhibitor class. See all Serine/threonine kinase inhibitor and PARP inhibitor drugs at /class/serine-threonine-kinase-inhibitor-and-parp-inhibitor.
What development phase is Administration of ceralasertib and olaparib in?
Administration of ceralasertib and olaparib is in Phase 1.
What are the side effects of Administration of ceralasertib and olaparib?
Common side effects of Administration of ceralasertib and olaparib include Nausea, Fatigue, Vomiting.
What does Administration of ceralasertib and olaparib target?
Administration of ceralasertib and olaparib targets ATR and PARP1 and is a Serine/threonine kinase inhibitor and PARP inhibitor.
Related
- Drug class: All Serine/threonine kinase inhibitor and PARP inhibitor drugs
- Target: All drugs targeting ATR and PARP1
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer
- Indication: Drugs for Ovarian cancer
- Compare: Administration of ceralasertib and olaparib vs similar drugs
- Pricing: Administration of ceralasertib and olaparib cost, discount & access